Comparative Pharmacology
Head-to-head clinical analysis: CLORAZEPATE DIPOTASSIUM versus VERSED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLORAZEPATE DIPOTASSIUM versus VERSED.
CLORAZEPATE DIPOTASSIUM vs VERSED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on gamma-aminobutyric acid type A (GABAA) receptors, enhancing GABA-mediated chloride ion influx, leading to neuronal hyperpolarization and decreased excitability.
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and causing neuronal hyperpolarization.
15-60 mg/day orally in divided doses 2-4 times daily; usual starting dose 15 mg at bedtime or 15 mg twice daily.
IV: Initial 1-2.5 mg; titrate by 0.5-1 mg every 2-3 min; usual total 2.5-5 mg for sedation. IM: 0.07-0.08 mg/kg (max 5 mg) once. Oral: 7.5-15 mg once (preoperative).
None Documented
None Documented
40-50 hours (clorazepate is a prodrug rapidly converted to nordiazepam); effective half-life of nordiazepam is 40-100 hours. Accumulation occurs with repeated dosing, leading to prolonged sedation in elderly or hepatic impairment.
Terminal elimination half-life: 1.8–2.5 hours in healthy adults; prolonged in elderly (up to 6 hours), obesity (up to 8 hours), hepatic cirrhosis (up to 20 hours), and critically ill patients.
Primarily renal (60-70% as oxazepam glucuronide and other metabolites), with 15-20% biliary/fecal elimination. Less than 1% excreted unchanged.
Renal: ~1% unchanged; Hepatic metabolism to glucuronide conjugates and 1-hydroxymidazolam, with subsequent renal elimination of metabolites. Fecal excretion is minimal (<2%).
Category D/X
Category C
Benzodiazepine
Benzodiazepine